Targeting tumor-associated macrophages to synergize tumor immunotherapy
X Xiang, J Wang, D Lu, X Xu - Signal transduction and targeted therapy, 2021 - nature.com
The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …
immunotherapies have raised hope for a successful control of these advanced diseases, but …
Beyond immune checkpoint blockade: emerging immunological strategies
The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
Cervical cancer immunotherapy: facts and hopes
It is a sad fact that despite being almost completely preventable through human
papillomavirus (HPV) vaccination and screening, cervical cancer remains the fourth most …
papillomavirus (HPV) vaccination and screening, cervical cancer remains the fourth most …
[HTML][HTML] Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal,
or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial - PMC Back to Top …
or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial - PMC Back to Top …
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label …
TY Seiwert, B Burtness, R Mehra, J Weiss… - The lancet …, 2016 - thelancet.com
Background Patients with recurrent or metastatic squamous cell carcinoma of the head and
neck have few treatment options. We aimed to assess the safety, tolerability, and antitumour …
neck have few treatment options. We aimed to assess the safety, tolerability, and antitumour …
[HTML][HTML] Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study
J Bauml, TY Seiwert, DG Pfister, F Worden… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose There are no approved treatments for recurrent/metastatic head and neck
squamous cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II …
squamous cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II …
[HTML][HTML] PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
Background Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma …
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma …
[HTML][HTML] Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from …
Purpose Treatment with pembrolizumab, an anti–programmed death-1 antibody, at 10
mg/kg administered once every 2 weeks, displayed durable antitumor activity in …
mg/kg administered once every 2 weeks, displayed durable antitumor activity in …
[PDF][PDF] Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial
Purpose The KEYNOTE-028 trial (ClinicalTrials. gov identifier: NCT02054806) was
designed to assess the safety and efficacy of pembrolizumab in 20 programmed death …
designed to assess the safety and efficacy of pembrolizumab in 20 programmed death …